Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jun 4;135(23):2033-2040.
doi: 10.1182/blood.2020006000.

COVID-19 and its implications for thrombosis and anticoagulation

Jean M Connors  1 , Jerrold H Levy  2   3   4
Affiliations

COVID-19 and its implications for thrombosis and anticoagulation

Jean M Connors et al. Blood. .

Abstract

Severe acute respiratory syndrome coronavirus 2, coronavirus disease 2019 (COVID-19)-induced infection can be associated with a coagulopathy, findings consistent with infection-induced inflammatory changes as observed in patients with disseminated intravascular coagulopathy (DIC). The lack of prior immunity to COVID-19 has resulted in large numbers of infected patients across the globe and uncertainty regarding management of the complications that arise in the course of this viral illness. The lungs are the target organ for COVID-19; patients develop acute lung injury that can progress to respiratory failure, although multiorgan failure can also occur. The initial coagulopathy of COVID-19 presents with prominent elevation of D-dimer and fibrin/fibrinogen-degradation products, whereas abnormalities in prothrombin time, partial thromboplastin time, and platelet counts are relatively uncommon in initial presentations. Coagulation test screening, including the measurement of D-dimer and fibrinogen levels, is suggested. COVID-19-associated coagulopathy should be managed as it would be for any critically ill patient, following the established practice of using thromboembolic prophylaxis for critically ill hospitalized patients, and standard supportive care measures for those with sepsis-induced coagulopathy or DIC. Although D-dimer, sepsis physiology, and consumptive coagulopathy are indicators of mortality, current data do not suggest the use of full-intensity anticoagulation doses unless otherwise clinically indicated. Even though there is an associated coagulopathy with COVID-19, bleeding manifestations, even in those with DIC, have not been reported. If bleeding does occur, standard guidelines for the management of DIC and bleeding should be followed.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: J.M.C. received personal fees from Bristol-Myers Squibb, Abbott, Portola, and Pfizer; and received research funding to the institution from CSL Behring. J.H.L. serves on research, data safety, or advisory committees for CSL Behring, Instrumentation Labs, Janssen, Merck, and Octapharma.

Comment in

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Layton DS, Choudhary A, Bean AGD. Breaking the chain of zoonoses through biosecurity in livestock. Vaccine. 2017;35(44):5967-5973. - PubMed
    1. Wu F, Zhao S, Yu B, et al. . A new coronavirus associated with human respiratory disease in China [published correction appears in Nature. 2020;580(7803):E7]. Nature. 2020;579(7798):265-269. - PMC - PubMed
    1. Hulswit RJ, de Haan CA, Bosch BJ. Coronavirus spike protein and tropism changes. Adv Virus Res. 2016;96:29-57. - PMC - PubMed
    1. Lu R, Zhao X, Li J, et al. . Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395(10224):565-574. - PMC - PubMed
    1. Schnittler HJ, Feldmann H. Viral hemorrhagic fever--a vascular disease? Thromb Haemost. 2003;89(6):967-972. - PubMed

MeSH terms

Substances